This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in
patients with relapsing forms of MS.
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Research Site, Guaynabo 00969, Puerto Rico
Research Site, Phoenix, Arizona 85006, United States
Research Site, Fresno, California 93720, United States
Research Site, Atlanta, Georgia 30327, United States
Research Site, Idaho Falls, Idaho 83404, United States
Research Site, Evanston, Illinois 60201, United States
Research Site, Lake Barrington, Illinois 60010, United States
Research Site, Indianapolis, Indiana 46256, United States
Research Site, West Des Moines, Iowa 50314, United States
Research Site, Lexington, Kentucky 40503, United States
Research Site, Louisville, Kentucky 40202, United States
Research Site, Boston, Massachusetts 02135, United States
Research Site, Lexington, Massachusetts 2421, United States
Research Site, Farmington Hills, Michigan 48334, United States
Research Site, Buffalo, New York 14203, United States
Research Site, New York, New York 10003-3804, United States
Research Site, Patchogue, New York 11772, United States
Research Site, Chapel Hill, North Carolina 27599, United States
Research Site, High Point, North Carolina 27262, United States
Research Site, Raleigh, North Carolina 27607, United States
Research Site, Portland, Oregon 97225, United States
Research Site, Anderson, South Carolina 29621, United States
Research Site, Franklin, Tennessee 37064, United States
Research Site, Knoxville, Tennessee 37934, United States
Research Site, Nashville, Tennessee 37212, United States
Research Site, Nashville, Tennessee 37205, United States
Research Site, Salt Lake City, Utah 84103, United States
Research Site, Salt Lake City, Utah 84108, United States
Research Site, Seattle, Washington 98195-6097, United States
Research Site, Charleston, West Virginia 25301, United States
Research Site, Waukesha, Wisconsin 53188, United States